Overview

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
George Albert Fisher
Collaborator:
Genentech, Inc.
Treatments:
Erlotinib Hydrochloride
Pertuzumab